Baxter International (BAX) just unveiled an update.
Baxter International Inc. has agreed to sell its renal care and acute therapies business to a consortium led by global investment firm Carlyle for $3.8 billion, with expected net proceeds of approximately $3 billion. The comprehensive deal includes the divestiture of several Baxter entities and is subject to regulatory approvals, with completion anticipated by early 2025. Following the sale, Baxter will focus on its core medical products while retaining its saline and plastics operations, and the parties involved will continue to collaborate via manufacturing, supply, and service agreements.
Find detailed analytics on BAX stock on TipRanks’ Stock Analysis page.
